Study at a glance
What was the question?
Why do vitamin D studies reach different conclusions about autoimmunity? The review asks whether they measured the same exposure, disease stage and outcome before trying to explain the difference.
Who or what was studied?
Two investigations followed children at increased risk of type 1 diabetes. Two used inherited genetic variants to study vitamin D status and disease susceptibility. Additional brain and mouse research helped explain the limits of tissue and immune measurements.
What did the studies find?
The childhood associations differed. One genetic analysis supported a role for lower vitamin D status in multiple sclerosis susceptibility. The type 1 diabetes genetic analysis did not establish a clear overall effect. These studies used different instruments, populations and outcomes; the contrast alone does not prove that their true effects differ.
What does this mean?
A genetic tendency over life is not the same as starting supplements now. Timing and tissue context can matter, but they do not automatically explain every disagreement. A result that is not statistically clear does not prove zero effect. These findings do not establish a personal blood target, genetic treatment test or supplement plan.
Read the full article below ↓Different vitamin D studies do not necessarily estimate the same effect. Some follow measured blood status before early autoimmune markers. Others use inherited genetic variants to study lifelong tendencies and disease susceptibility. This review compares those approaches without assuming that every difference has one biological explanation. For the detailed analysis, read Why Vitamin D Autoimmune Findings Differ: Full Evidence Review.
The childhood observations did not agree consistently
TEDDY linked higher measured vitamin D status with lower odds of persistent islet autoantibodies in children at increased genetic risk of type 1 diabetes. DAISY did not find a clear measured-status association with autoimmunity or progression to diabetes. Their exposure scales, measurement windows and analysis groups differed. Neither was a randomized prevention trial. [1] [2]
TEDDY also found evidence that an association varied with a receptor variant. The strength of this interaction depended on the time window and adjustment for multiple tests. It does not establish a genetic test for choosing a supplement regimen. The childhood average included first antibody detection, so the entire exposure cannot be placed before biological initiation.
Vitamin D and Immune Tolerance concerns restraint of self-directed immunity. Detecting an antibody, showing functional suppression and diagnosing disease are different measurements of that wider process. Their timing cannot be treated as interchangeable.
Genetic analyses asked a different question
Mendelian randomization uses variants associated with an exposure to examine its possible effect on an outcome. It can reduce some problems of disease altering the measured exposure. It still depends on assumptions about the variants, including whether they influence disease through other routes. Vitamin D Genetics provides background on interpreting genetic evidence without individual determinism.
Mokry’s multiple-sclerosis study supported an association between genetically influenced lower vitamin D status and greater MS susceptibility. Its sensitivity analyses supported the interpretation but could not prove every genetic assumption. The published correction added an author and repaired a pathway figure; the corrected material was assessed. The result is not an adult supplementation trial. [10]
Manousaki’s type 1 diabetes analysis did not establish a clear overall effect. Its confidence interval allowed a range of effects, and a sensitivity analysis identified outlier-related pleiotropy. Removing outliers did not produce a significant association. A background-reference correction was assessed. Other panel and sample-total discrepancies are retained as limitations rather than used for unsupported numerical claims. [11]
Why a positive result and a null result are not a complete explanation
A clear result in one disease and a non-significant result in another do not themselves prove that the true effects differ. These analyses used different instruments and datasets. A lifelong genetic tendency is not equivalent to starting a supplement now, and a null average estimate cannot settle every possible timing or nonlinear question. Those remaining possibilities are hypotheses, not demonstrated benefits.
Additional evidence illustrates context without explaining the genetic contrast. Ramasamy measured regional expression in healthy brain, not hormone production in diseased lesions. Driver showed how receptor-deficient mice’s metabolic context could affect diabetes expression; unavailable supplementary figures limit detailed immune-function claims. Casteels tested functional cell transfer in a perturbed mouse model; a missing figure caption limits apoptosis detail. These remain three separate, bounded observations. [7] [4] [5]
Vitamin D and the Timing of Immune Activation and Restraint: Full Evidence Review explains why timing needs to be measured, not merely proposed after results differ. The selected evidence supports disease-specific interpretation: supportive MS genetic findings, uncertain childhood associations and no clear overall T1D genetic effect. It does not support a universal autoimmune prevention claim or genotype-guided self-treatment.
Scientific sources and access
Evidence assessed on 5 November 2026. This is an original synthesis of selected research, not a reproduction of the papers or a systematic review. Material source-access limits are identified in the analysis.
[1] Norris and colleagues. Plasma 25-Hydroxyvitamin D Concentration and Risk of Islet Autoimmunity. Diabetes. 2018 Jan;67(1):146 to 154. DOI: 10.2337/db17-0802. PMID: 29061729.
[2] Simpson and colleagues. No association of vitamin D intake or 25-hydroxyvitamin D levels in childhood with risk of islet autoimmunity and type 1 diabetes: the Diabetes Autoimmunity Study in the Young (DAISY). Diabetologia. 2011 Nov;54(11):2779 to 2788. DOI: 10.1007/s00125-011-2278-2. PMID: 21858504.
[4] Driver and colleagues. Calcium insufficiency accelerates type 1 diabetes in vitamin D receptor-deficient nonobese diabetic (NOD) mice. Endocrinology. 2011 Dec;152(12):4620 to 4629. DOI: 10.1210/en.2011-1074. PMID: 21952242.
[5] Casteels and colleagues. 1,25-Dihydroxyvitamin D3 restores sensitivity to cyclophosphamide-induced apoptosis in non-obese diabetic (NOD) mice and protects against diabetes. Clinical and experimental immunology. 1998 May;112(2):181 to 187. DOI: 10.1046/j.1365-2249.1998.00568.x. PMID: 9649179.
[7] Ramasamy and colleagues. Genetic evidence for a pathogenic role for the vitamin D3 metabolizing enzyme CYP24A1 in multiple sclerosis. Multiple sclerosis and related disorders. 2014 Mar;3(2):211 to 219. DOI: 10.1016/j.msard.2013.08.009. PMID: 25568836.
[10] Mokry and colleagues. Vitamin D and Risk of Multiple Sclerosis: A Mendelian Randomization Study. PLoS medicine. 2015 Aug;12(8):e1001866. DOI: 10.1371/journal.pmed.1001866. PMID: 26305103.
[11] Manousaki and colleagues. Vitamin D levels and risk of type 1 diabetes: A Mendelian randomization study. PLoS medicine. 2021 Feb;18(2):e1003536. DOI: 10.1371/journal.pmed.1003536. PMID: 33630834.
Mokry and colleagues. Correction: Vitamin D and Risk of Multiple Sclerosis: A Mendelian Randomization Study. PLOS Medicine. 2016. DOI: 10.1371/journal.pmed.1001981. PMID: 26963823.
Manousaki and colleagues. Correction: Vitamin D levels and risk of type 1 diabetes: A Mendelian randomization study. PLOS Medicine. 2021. DOI: 10.1371/journal.pmed.1003624. PMID: 33914743.
Related reading
High frequency of vitamin D receptor gene polymorphism FokI in Brazilian Type 1 diabetes mellitus patients with clinical autoimmune thyroid disease
The aim of this study was to evaluate the relationship between VDR FokI polymorphism (rs10735810), thyroid autoimmunity and thyroid dysfunction (TD) in Brazilian T1DM.
Original paper ↗Read more →Type 1 Diabetes and Other Autoimmune Diseases: Epidemiology, Pathophysiology and Screening
A comprehensive review of literature on T1D and associated AID was conducted, with the aim of drawing informed conclusions relevant to clinical practice.
Original paper ↗Read more →The Relationship Between Autoimmune Disorders and Multiple Sclerosis: Clinical Insights and Therapeutic Approaches
This study investigated the prevalence of AIDs among Polish patients with MS (PwMSs) and its potential effects on disease characteristics.
Original paper ↗Read more →Altered Expression of Vitamin D Metabolism Genes and Circulating MicroRNAs in PBMCs of Patients with Type 1 Diabetes: Their Association with Vitamin D Status and Ongoing Islet Autoimmunity
This study aimed to decipher differences in the expression of genes associated with vitamin D metabolism in T1DM patients and to ascertain if there is a correlation between serum 1,25(OH)2D3 levels and the expression of these genes.
Original paper ↗Read more →Type 1 Diabetes Autoimmunity: To What Extent Vitamin D is Beneficial
Moreover, the coupled therapy and clinical trials that have investigated the use of vitamin D as a therapeutic intervention for autoimmune disorders were also examined, highlighting both successes and limitations.
Original paper ↗Read more →The Footprints of Poly-Autoimmunity: Evidence for Common Biological Factors Involved in Multiple Sclerosis and Hashimoto’s Thyroiditis
Although the biological implications of these data need to be further investigated, we have highlighted the relevance of studies comparing different autoimmune pathologies for the understanding of the core concepts of autoimmunity.
Original paper ↗Read more →Combination therapy with saxagliptin and vitamin D for the preservation of β-cell function in adult-onset type 1 diabetes: a multi-center, randomized, controlled trial
Here, we conducted a multi-centre, randomized, controlled trial to assess the β-cell preservation effects of saxagliptin alone and saxagliptin combined with vitamin D as adjunctive therapies in adult-onset autoimmune type 1 diabetes.
Original paper ↗Read more →Combined Use of Vitamin D and DPP-4 Inhibitors as a Potential Adjuvant Treatment Strategy to Enhance the Efficacy of Novel Beta-Cell Replacement Therapies for Type 1 Diabetes
Emerging evidence suggests that vitamin D and dipeptidyl peptidase-4 (DPP-4) inhibitors exert synergistic immunomodulatory, anti-inflammatory and antioxidant actions.
Original paper ↗Read more →Effect of Calcitriol on Bone Turnover and Osteocalcin in Recent-Onset Type 1 Diabetes
We investigated the effect of supplementation with calcitriol on bone turnover in recent-onset type 1 diabetes (T1D).
Original paper ↗Read more →Immunomodulatory Effect of Vitamin D and Its Potential Role in the Prevention and Treatment of Type 1 Diabetes Mellitus: A Narrative Review
The aim of this narrative review is to present the molecular mechanisms for the vitamin D immunomodulatory effect as well as review human clinical studies on the use of vitamin D as adjuvant therapy in type 1 diabetes mellitus.
Original paper ↗Read more →Leptin and IGF-1 in Infancy Are Associated With Variants in DHCR7 and CYP2R1 That Relate With Type 1 Diabetes and 25OHD
Vitamin D has been variably implicated in risk of developing type 1 diabetes based on cohorts of at-risk individuals.
Original paper ↗Read more →Prevalence and characteristics of overweight/obesity in children newly diagnosed with type 1 diabetes in Kuwait
Overweight/obese children were older at diagnosis compared to non-obese children (median age 9.3 vs.
Original paper ↗Read more →Combined Therapy of Vitamin D3-Tolerogenic Dendritic Cells and Interferon-β in a Preclinical Model of Multiple Sclerosis
For this purpose, we analyzed the efficacy of a combined therapy based on the use of vitamin D3 (VitD3)-tolDC plus interferon beta (IFN-beta) in MS.
Original paper ↗Read more →COVID-19 and Multiple Sclerosis: A Complex Relationship Possibly Aggravated by Low Vitamin D Levels
COVID-19 can evolve into a severe disease associated with immediate and delayed sequelae in different organs, including the central nervous system (CNS).
Original paper ↗Read more →Cryopreserved vitamin D3-tolerogenic dendritic cells pulsed with autoantigens as a potential therapy for multiple sclerosis patients
Tolerogenic dendritic cells (tolDC) have been postulated as a potent immunoregulatory therapy for autoimmune diseases such as multiple sclerosis (MS).
Original paper ↗Read more →Disability progression in multiple sclerosis: a latent class analysis of predictors
We aimed to identify patterns of disability progression and their determinants to improve individualized risk assessment and support clinical decision-making.
Original paper ↗Read more →Linking Mechanisms of Vitamin D Signaling with Multiple Sclerosis
Environmental triggers often work via signal transduction cascades that modulate the epigenome and transcriptome of cell types involved in the disease process.
Original paper ↗Read more →Vitamin D as a Potential Therapy for Multiple Sclerosis: Where Are We?
Disease-modifying medications, which mainly aim to suppress such aberrant immune response, have significantly improved MS treatment.
Original paper ↗Read more →Why Vitamin D Autoimmune Findings Differ: Full Evidence Review
Compare childhood cohorts and genetic studies of multiple sclerosis and type 1 diabetes, with timing, measurement and causal limits explained.
Read more →How to Read Vitamin D Evidence in Autoimmunity
Distinguish autoantibodies, cell-transfer tests, tissue measurements and genetic risk estimates when reading vitamin D autoimmune research.
Read more →Dietary Interventions in Multiple Sclerosis: Development and Pilot-Testing of an Evidence Based Patient Education Program
Fifteen randomised-controlled trials (RCTs) were included in the systematic review.
Original paper ↗Read more →Original sources
Plasma 25-Hydroxyvitamin D Concentration and Risk of Islet Autoimmunity
[1] Norris and colleagues.
Publication details
[1] Norris and colleagues. Plasma 25-Hydroxyvitamin D Concentration and Risk of Islet Autoimmunity. Diabetes. 2018 Jan;67(1):146 to 154. DOI: 10.2337/db17-0802. PMID: 29061729.
No association of vitamin D intake or 25-hydroxyvitamin D levels in childhood with risk of islet autoimmunity and type 1 diabetes: the Diabetes Autoimmunity Study in the Young (DAISY)
[2] Simpson and colleagues.
Publication details
[2] Simpson and colleagues. No association of vitamin D intake or 25-hydroxyvitamin D levels in childhood with risk of islet autoimmunity and type 1 diabetes: the Diabetes Autoimmunity Study in the Young (DAISY). Diabetologia. 2011 Nov;54(11):2779 to 2788. DOI: 10.1007/s00125-011-2278-2. PMID: 21858504.
Calcium insufficiency accelerates type 1 diabetes in vitamin D receptor-deficient nonobese diabetic (NOD) mice
[4] Driver and colleagues.
Publication details
[4] Driver and colleagues. Calcium insufficiency accelerates type 1 diabetes in vitamin D receptor-deficient nonobese diabetic (NOD) mice. Endocrinology. 2011 Dec;152(12):4620 to 4629. DOI: 10.1210/en.2011-1074. PMID: 21952242.
1,25-Dihydroxyvitamin D3 restores sensitivity to cyclophosphamide-induced apoptosis in non-obese diabetic (NOD) mice and protects against diabetes
Published in Clinical and experimental immunology. 1998 May;112(2):181 to 187. DOI: 10.1046/j.1365-2249 (1998).
Publication details
[5] Casteels and colleagues. 1,25-Dihydroxyvitamin D3 restores sensitivity to cyclophosphamide-induced apoptosis in non-obese diabetic (NOD) mice and protects against diabetes. Clinical and experimental immunology. 1998 May;112(2):181 to 187. DOI: 10.1046/j.1365-2249.1998.00568.x. PMID: 9649179.
Genetic evidence for a pathogenic role for the vitamin D3 metabolizing enzyme CYP24A1 in multiple sclerosis
Published in Multiple sclerosis and related disorders. 2014 Mar;3(2):211 to 219. DOI: 10.1016/j.msard (2013).
Publication details
[7] Ramasamy and colleagues. Genetic evidence for a pathogenic role for the vitamin D3 metabolizing enzyme CYP24A1 in multiple sclerosis. Multiple sclerosis and related disorders. 2014 Mar;3(2):211 to 219. DOI: 10.1016/j.msard.2013.08.009. PMID: 25568836.
Vitamin D and Risk of Multiple Sclerosis: A Mendelian Randomization Study
[10] Mokry and colleagues.
Publication details
[10] Mokry and colleagues. Vitamin D and Risk of Multiple Sclerosis: A Mendelian Randomization Study. PLoS medicine. 2015 Aug;12(8):e1001866. DOI: 10.1371/journal.pmed.1001866. PMID: 26305103.
Vitamin D levels and risk of type 1 diabetes: A Mendelian randomization study
[11] Manousaki and colleagues.
Publication details
[11] Manousaki and colleagues. Vitamin D levels and risk of type 1 diabetes: A Mendelian randomization study. PLoS medicine. 2021 Feb;18(2):e1003536. DOI: 10.1371/journal.pmed.1003536. PMID: 33630834.
Correction: Vitamin D and Risk of Multiple Sclerosis: A Mendelian Randomization Study
Published in PLOS Medicine (2016).
Publication details
Mokry and colleagues. Correction: Vitamin D and Risk of Multiple Sclerosis: A Mendelian Randomization Study. PLOS Medicine. 2016. DOI: 10.1371/journal.pmed.1001981. PMID: 26963823.
Correction: Vitamin D levels and risk of type 1 diabetes: A Mendelian randomization study
Published in PLOS Medicine (2021).
Publication details
Manousaki and colleagues. Correction: Vitamin D levels and risk of type 1 diabetes: A Mendelian randomization study. PLOS Medicine. 2021. DOI: 10.1371/journal.pmed.1003624. PMID: 33914743.